Furthermore, oxaliplatin and the anti-EGFR antibody cetuximab can induce immunogenic cell death in cancer cells that directly lead to activation of tumor reactive T cells and expression of the co-inhibitory receptors PD-L1 and LAG3 (12, 13). The gene discussed is EGFR; the disease is neoplasm.